Is AbbVie (ABBV) Undervalued As It Expands Skyrizi In Crohns Disease?
Yahoo Finance · Aug 30, 2026 · Apogee Therapeutics, Inc. Common Stock (APGE)
What AbbVie’s Skyrizi EMA filing means for ABBV stock AbbVie (ABBV) has moved to expand Skyrizi’s role in Crohn's disease treatment by submitting an application to the European Medicines Agency for a subcutaneous induction regimen in adults with moderately to severely active disease. The filing, backed by Phase 3 AFFIRM data, comes as AbbVie stock reflects a mixed recent pattern, with the share price down over the past week but higher over the past month, past 3 months and past year. At a...
Not investment advice. Cached headline, not a full reprint.